CARDIOL THERAPEUTICS INC-A (CRDL) Stock Price, Quote, News and Overview
NASDAQ:CRDL - Nasdaq - CA14161Y2006 - Common Stock - Currency: USD
CRDL Quote, Performance and Key Statistics
1.2
-0.1 (-7.69%)
The current stock price of CRDL is 1.2 USD. In the past month the price decreased by -11.76%. In the past year, price decreased by -25.93%.
CRDL Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 67.21 | 829.40B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 27.44 | 390.99B | ||
| JNJ | JOHNSON & JOHNSON | 16.25 | 390.76B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 20.56 | 230.17B | ||
| MRK | MERCK & CO. INC. | 11.71 | 226.40B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.77 | 215.98B | ||
| PFE | PFIZER INC | 8.46 | 149.04B | ||
| SNY | SANOFI-ADR | 13.58 | 136.54B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 48.97 | 113.23B | ||
| GSK | GSK PLC-SPON ADR | 7.78 | 74.77B | ||
| ZTS | ZOETIS INC | 27.1 | 72.39B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.95 | 44.58B |
Related stock screener links
About CRDL
Company Profile
Cardiol Therapeutics, Inc. is a clinical-stage life sciences company focused on the research and clinical of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The company is headquartered in Oakville, Ontario. The company went IPO on 2018-12-20. The firm is focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. Its lead drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. The company is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with myocarditis, pericarditis, and heart failure. The company is also developing CRD-38, a novel subcutaneously administered drug intended for use in heart failure. The company has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart.
Company Info
CARDIOL THERAPEUTICS INC-A
602-2265 Upper Middle Road East
Oakville ONTARIO CA
Employees: 6
Company Website: https://www.cardiolrx.com/
Investor Relations: http://www.cardiolrx.com/investors/
Phone: 12899100850
CARDIOL THERAPEUTICS INC-A / CRDL FAQ
What is the stock price of CARDIOL THERAPEUTICS INC-A today?
The current stock price of CRDL is 1.2 USD. The price decreased by -7.69% in the last trading session.
What is the ticker symbol for CARDIOL THERAPEUTICS INC-A stock?
The exchange symbol of CARDIOL THERAPEUTICS INC-A is CRDL and it is listed on the Nasdaq exchange.
On which exchange is CRDL stock listed?
CRDL stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for CARDIOL THERAPEUTICS INC-A stock?
8 analysts have analysed CRDL and the average price target is 6.91 USD. This implies a price increase of 475.65% is expected in the next year compared to the current price of 1.2. Check the CARDIOL THERAPEUTICS INC-A stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CARDIOL THERAPEUTICS INC-A worth?
CARDIOL THERAPEUTICS INC-A (CRDL) has a market capitalization of 99.13M USD. This makes CRDL a Micro Cap stock.
How many employees does CARDIOL THERAPEUTICS INC-A have?
CARDIOL THERAPEUTICS INC-A (CRDL) currently has 6 employees.
What are the support and resistance levels for CARDIOL THERAPEUTICS INC-A (CRDL) stock?
CARDIOL THERAPEUTICS INC-A (CRDL) has a support level at 1.19 and a resistance level at 1.25. Check the full technical report for a detailed analysis of CRDL support and resistance levels.
Should I buy CARDIOL THERAPEUTICS INC-A (CRDL) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CRDL, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CRDL, evaluating the profitability, health, valuation and growth aspects
- CARDIOL THERAPEUTICS INC-A (CRDL) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CARDIOL THERAPEUTICS INC-A (CRDL) Sales and EPS estimates to see what analysts future expectations are.
- CARDIOL THERAPEUTICS INC-A (CRDL) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CARDIOL THERAPEUTICS INC-A (CRDL) Insider and Institutional Ownership to learn about the owners and their transactions.
- CARDIOL THERAPEUTICS INC-A (CRDL) Stock Chart to make your own analysis
- CARDIOL THERAPEUTICS INC-A (CRDL) Latest news and press-releases to stay up to date.
Does CARDIOL THERAPEUTICS INC-A (CRDL) stock pay dividends?
CRDL does not pay a dividend.
When does CARDIOL THERAPEUTICS INC-A (CRDL) report earnings?
CARDIOL THERAPEUTICS INC-A (CRDL) will report earnings on 2025-03-31, after the market close.
What is the Price/Earnings (PE) ratio of CARDIOL THERAPEUTICS INC-A (CRDL)?
CARDIOL THERAPEUTICS INC-A (CRDL) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.38).
What is the Short Interest ratio of CARDIOL THERAPEUTICS INC-A (CRDL) stock?
The outstanding short interest for CARDIOL THERAPEUTICS INC-A (CRDL) is 1.82% of its float. Check the ownership tab for more information on the CRDL short interest.
CRDL Technical Analysis
CRDL Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to CRDL. CRDL has a bad profitability rating. Also its financial health evaluation is rather negative.
CRDL Financial Highlights
Over the last trailing twelve months CRDL reported a non-GAAP Earnings per Share(EPS) of -0.38. The EPS decreased by -22.73% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -206.26% | ||
| ROE | -346.42% | ||
| Debt/Equity | 0.01 |
CRDL Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to CRDL. The Buy consensus is the average rating of analysts ratings from 8 analysts.